Clover Corporation Limited · ASX:CLV

Clover — Shareholder Meeting (November 2016)

16 slides from Clover's shareholder meeting presentation, Nov 25, 2016

1. Slide 1: Annual General Meeting ASX announcement

   For personal use only &ORYHU&RUSRUDWLRQ/LPLWHG $%1 $6;$11281&(0(17 1RYHPEHU 7KH0DQDJHU &RPSDQ\$QQRXQFHPHQWV2IILFH $6;/LPLWHG %ULGJH6WUHHW 6<'1(<16: $118$/*(1(5$/0((7,1* (QFORVHGLVWKHWUDQVFULSWRIWKH&KDLUPDQ¶V$GGUHVVDQGDFRS\RIWKHSUHVHQWDWLRQE\WKH &(2ZKLFKDUHERWKWREHGHOLYHUHGDWWKH$QQXDO*HQHUDO0HHWLQJRI

2. Slide 2: Chairman's Address 2016

   Clover Corporation Limited Chairman’s Address 2016 I am pleased to inform shareholders of an improved year for Clover Corporation with revenues For personal use only up 43%, a net profit of $2.2 million; increased dividend payment and an upward movement in share price. These improvements are the res

3. Slide 3: Chairman's Address 2016 (continued)

   distributors, and the move to sell off inventory which will not achieve a licence under the new regulations. For personal use only Europe The EU released new infant formula regulations in February requiring that all infant formula sold in the EU must contain a minimum of 20mg of DHA per serve, an in

4. Slide 4: Managing Director's Report Months to July 2016

   For personal use only Managing Director’s Report 12 Months to 31 July 2016 25 November 2016

5. Slide 5: Vision and Mission Statement

   For personal use only Vision and Mission Statement Vision To optimise the health and development of adults, infants and children. Mission To deliver science based bioactives which provide health benefits to adults, infants, children and to the medical food markets. 1

6. Slide 6: Full Year Performance Highlights

   For personal use only Full Year Performance Highlights Total Revenue Strong growth in $42.9m up 43% non-traditional accounts & driven by improved demand pipeline of new opportunities Net Profit $2.2m up Inventory managed at on 2015 $0.1m $13.6m down 4% on prior year Operating expenses Balance

7. Slide 7: Full Year 2016 Results

   For personal use only Full Year 2016 Results AUD million 4E Reported 4E Reported  43% year on year revenue 31 Jul 2016 31 Jul 2015 growth Revenue $42.9 $29.9  Increased sales to EU, ANZ EBITDA $3.3 $0.6 and new customers EBIT $2.8 ($0.1)  EBIT $2.8m (PCP -$0.1m) NPBT $3.1 nil  Fixed costs manage

8. Slide 8: Balance Sheet July 2016

   For personal use only Balance Sheet 31 July 2016 AUD million Reported Reported Movement 31 July 2016 31 July 2015  Cash balance strong $8.2m Cash $8.2 $9.6 1.4  Trade $10.9 $5.5 5.4   Trade receivables Receivables & payables reflect Inventories $13.6 $14.2 0.6  the increased sales activity Tota

9. Slide 9: Sales by geography & product

   For personal use only Sales by geography & product  Asia, Australia & New  Encapsulated Tuna oil Zealand have grown during leads sales revenue with 2016. encapsulated Algal oils and  European and American other oils represented in markets provide new other products opportunities FY 2016 Geographi

10. Slide 10: An Update on Growth Platforms

    For personal use only An Update on Growth Platforms Focus on infant formula customers and market Products and Market Development Research & Development 6

11. Slide 11: Growth Platform: Focus on infant formula customers and market

    For personal use only Focus on Growth Platform infant formula customers Continued focus on the infant formula market and market  New Chinese Infant Formula regulations were released on October 1 requiring manufacturers to re-license and have a maximum of three brands with three scientifically diffe

12. Slide 12: Growth Platform: Focus on infant formula customers and market

    For personal use only Focus on Growth Platform infant formula customers Continued focus on the infant formula market and market  New European regulations requiring the inclusion of a minimum 20mg DHA dosage in all infant formula by 2020 has Clover working with existing and new customers to achieve

13. Slide 13: Growth Platform: Products and Market Development

    For personal use only Growth Platform Products and Market Developing new markets Development  Clover has appointed a new distributor in the EU market focused on achieving sales in the second tier Infant formula market, food, sport nutrition and nutraceuticals.  Clover has appointed a distributor i

14. Slide 14: Growth Platform: Research & Development

    For personal use only Growth Platform Research & Development Research & Development Strengthened  Clover has developed a new product which was launched at the Supply Side West show in Las Vegas, the product is a encapsulated powder containing 60% oil, which is a GRAS approved concentrate targeting

15. Slide 15: FY2017 Outlook & Priorities

    For personal use only FY2017 Outlook & Priorities  Market development into the EU taking advantage of new regulations  Develop new product applications into sports nutrition and nutraceutical market segments  Maintaining growth in Oceania, Asia and Europe  Research & Development in collaboration

16. Slide 16: Disclaimer

    For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s

Clover — Shareholder Meeting (November 2016) on 6ix